Condition
Locally Advanced Nasopharyngeal Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Locally Advanced Nasopharyngeal Carcinoma clinical trials that are recruiting, in China. By phase: Phase 3 (3), Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1Country
Newest Locally Advanced Nasopharyngeal Carcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Serplulimab with Induction Chemotherapy and Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma | Phase 3 | Wuhan, Hubei | Recruiting | Sep 17, 2025 |
| Iparomlimab/Tuvorlimab (QL1706) plus modified TPF induction for locally advanced nasopharyngeal carcinoma | Phase 2 | Xiamen, Fujian | Recruiting | Jul 25, 2025 |
| Using immunonutrition to reduce oral mucositis in nasopharyngeal carcinoma patients after treatment | — | Fuzhou, Fujian and 19 other locations | Recruiting | Jun 7, 2023 |
| Comparing two versus three cycles of chemotherapy for advanced nasopharyngeal cancer | Phase 3 | Guangzhou, Other (Non U.s.) | Recruiting | May 16, 2023 |
| Combining Envafolimab with Chemoradiotherapy for Advanced Nasopharyngeal Cancer | Phase 2 | Guangzhou, Guangdong | Recruiting | May 31, 2022 |
| Comparing two treatment approaches for advanced nasopharyngeal cancer | Phase 3 | Guangzhou, Guangdong | Recruiting | Sep 30, 2021 |
All recruiting trials (6)
-
Serplulimab with Induction Chemotherapy and Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
This phase 3 trial tests whether giving serplulimab with induction chemotherapy and radiotherapy, then maintenance therapy, can help people with locally advanced nasopharyngeal cancer who respond well to initial chemotherapy.
-
Iparomlimab/Tuvorlimab (QL1706) plus modified TPF induction for locally advanced nasopharyngeal carcinoma
This trial will test whether adding the dual-antibody Iparomlimab/Tuvorlimab (QL‑1706) to a modified TPF chemotherapy regimen as induction therapy helps adults with newly diagnosed, locally advanced nasopharyngeal carcinoma.
-
Using immunonutrition to reduce oral mucositis in nasopharyngeal carcinoma patients after treatment
This study is testing if a special type of nutrition can help reduce painful mouth sores in patients with nasopharyngeal cancer who are getting treatment.
-
Comparing two versus three cycles of chemotherapy for advanced nasopharyngeal cancer
This study is testing whether two cycles of chemotherapy before radiation is just as effective as three cycles for people with advanced nasopharyngeal cancer.
-
Combining Envafolimab with Chemoradiotherapy for Advanced Nasopharyngeal Cancer
This study is testing if combining a new drug called Envafolimab with standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer live longer without their cancer getting worse.
-
Comparing two treatment approaches for advanced nasopharyngeal cancer
This study is testing two different treatment plans for advanced nasopharyngeal cancer to see if one works just as well as the other for patients.
Related topics
Quick answers
How many Locally Advanced Nasopharyngeal Carcinoma clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.